

26 Mar 2023 | News

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast version of Five Must-Know Things: ripples from SVB's failure; Karuna's schizophrenia win; big pharma remains open to partnering; ChatGPT comes to medical congresses; and China's COVID vaccine lessons.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 24 March 2023, including: ripples from SVB's failure; [Karuna Therapeutics, Inc.](#)'s schizophrenia win; big pharma remains open to partnering; ChatGPT comes to medical congresses; and China's COVID vaccine lessons.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Is SVB Failure A Sign Of More Uncertainty On The Horizon?](#)" - Scrip, 21 Mar, 2023.)

(Also see "[Karuna Three-For-Three As Another KarXT Schizophrenia Trial Hits Primary Endpoint](#)" - Scrip, 20 Mar, 2023.)

(Also see "[Pharma Giants Urge Biotechs To Get In Touch As Early As Possible](#)" - Scrip, 20 Mar, 2023.)

(Also see "[The ChatGPT Revolution Comes To Pharma Business, Starting With Medical Congresses](#)" - Scrip, 22 Mar, 2023.)

(Also see "[COVID Lessons Mean New Vaccine Approach Needed In China, Exec Says](#)" - Scrip, 21 Mar, 2023.)

[Click here to explore this interactive content online](#) 